Aim To a review the prevention with probucol in subjects with high risk of cardiovascular disease. Methods The relevant information on the outcome events of probucol treatment was extracted from papers of Multifactorial Primary Prevention Trial of Vascular Disease in Finland to analyze the effect of probucol on coronary events. Results Probucol,especially when combined with clofibrate,markedly reduced high density lipoprotein cholesterol. The number of coronary events was higher than predictive values in those men who had been treated with clofibrate and beta-blockers but it is lower with probucol added. Five years cumulative incidence of coronary events is different in group with probucol added and without probucol added (1.0% vs 3.6%,P=0.040). Taking into account the impact of different drugs,there were significant association between probucol and coronary events (RR was 0.186,95%CI was 0.053 to 0.656,P=0.008). Conclusion Although probucol decreased high density lipoprotein cholesterol levels,if cholesterol levels remained high,other drugs combined with probucot can stiu reduce coronary events in high risk subjects.